Fig. 4

Long-term outcome following single-lung transplantation in interstitial lung disease (ILD) recipients. (A) Overall survival was ascertained by considering death from any cause as an event. (B) Freedom from chronic lung allograft dysfunction (CLAD) was ascertained by development of CLAD as an event. (C) CLAD-free survival was assessed by considering events comprising both the development of CLAD and death from any cause. In cases where no such events occurred, the date of the last follow-up was employed for censoring. The number of recipients at risk was recorded at various time points throughout the duration of the study